
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Special considerations and cautions must be adhered to when designing virus safety studies and developing appropriate virus contamination control programs.
over 25 years ago
Outsourcing Outlookover 25 years ago
Managing Risks and Resourcesover 25 years ago
Blister News: COC Resin, Foil, and Lidding Innovationsover 25 years ago
Managing the Risks in Outsourcingover 25 years ago
Systemic Drug Delivery via the Buccal Mucosal Route





